Faisal Zain is a distinguished healthcare expert with a deep background in medical technology and the manufacturing of diagnostic and treatment devices. His work often sits at the intersection of laboratory innovation and commercial viability, giving him a front-row seat to the complex decisions pharmaceutical companies must make when clinical data doesn’t meet expectations. In this discussion, we dive into the recent strategic shifts within the sickle cell disease landscape, focusing on the hurdles of drug differentiation, the regulatory pressure on new molecules, and the path forward for established therapies after the discontinuation of promising new candidates.
The decision to halt development on tebapivat was a significant move for Agios, especially given the promise of once-daily dosing. What went wrong during the Phase 2 trials that led to this pivot?
The clinical reality is that convenience can never fully compensate for a lack of clear, dose-dependent efficacy in a crowded market. While the Phase 2 results for tebapivat did show some improvement in low hemoglobin levels and a reduction in red blood cell destruction, the data simply didn’t provide a competitive edge. It was frustrating to see that the response wasn’t dose-dependent, which is often a red flag for long-term viability in such a complex disease. Ultimately, the results weren’t strong enough to stand out against the Phase 3 data already achieved by their own foundational drug, mitapivat, in this same indication. When you have two internal molecules competing, the one that offers the most robust clinical evidence is always going to win, even if it requires a twice-daily pill instead of just one.
How does this setback change the competitive dynamic between Agios and other major players like Novo Nordisk in the sickle cell market?
This pivot places an immense amount of pressure on the commercial execution for mitapivat, as tebapivat was essentially the company’s best shot at directly challenging Novo Nordisk’s PKR activator, etavopivat. Following the Phase 3 results reported in April for etavopivat, the market expected a fight for dominance based on dosing frequency and patient adherence. Now that tebapivat is off the table, the competition becomes about who can capture the market first and maintain the trust of the medical community. Agios now has to lean heavily on its established reputation with mitapivat, which is already marketed under the brand name Aqvesme for other hemoglobin disorders like thalassemia. It’s no longer a race of multiple molecules, but a singular focus on making mitapivat the gold standard before the competition gains more ground.
The sickle cell community has faced several high-profile drug withdrawals and trial failures recently. Could you put the tebapivat news into context with these broader industry challenges?
It has been a heartbreaking series of setbacks for patients who are desperate for new options to manage this debilitating disease. Earlier this year, Pfizer had to voluntarily withdraw Oxbryta from the market after post-marketing studies revealed a higher risk of complications and deaths, which sent shockwaves through the community. We also saw Fulcrum Therapeutics stop their work on pociredir because of the FDA’s concerns that the entire class of molecules carried a risk of causing cancer. In that context, the failure of tebapivat to differentiate itself feels like another door closing, though it is perhaps a safer, more calculated exit than a safety-related withdrawal. For a community that has lived through these disappointing developments, every clinical failure feels like a personal loss for the families waiting for a breakthrough.
Agios is now putting all its weight behind mitapivat for a label expansion into sickle cell disease. What makes this drug a more stable bet for the FDA’s upcoming decision?
Mitapivat is a known quantity with a track record that gives the industry a bit more breathing room during a period of high volatility. It is already approved as Pyrukynd for treating anemia in rare PK deficiency, and last December, it picked up an approval for alpha- and beta-thalassemia. Because the FDA has granted it Priority Review for sickle cell disease, we are looking at a very tight timeline with a target decision date of November 1. The agency is looking for treatments that address a significant unmet need, and mitapivat’s extensive clinical experience offers a level of safety and efficacy data that tebapivat just couldn’t match. By focusing on this foundational PK activator, the company is betting that a proven, first-in-class medicine is exactly what the sickle cell community needs right now.
What is your forecast for sickle cell disease treatments?
I expect to see a period of intense consolidation where only the most robust and safety-proven molecules survive the FDA’s increasingly rigorous scrutiny. The recent wave of failures, particularly those involving cancer risks and post-marketing safety issues, has set a very high bar for any new oral small molecules entering the space. While the loss of tebapivat is a blow to dosing convenience, the likely approval of mitapivat later this year will offer a much-needed stabilization point for the market. Moving forward, I believe the industry will move away from risky, unproven classes and instead focus on expanding the labels of established PKR activators that have already demonstrated long-term safety in other rare blood disorders.
